A judicial source confirmed to CNBC on Tuesday that the Parquet National Financier, the French financial prosecutor, opened a preliminary investigation in March 2023 into counts of"dissemination of false or misleading information and price manipulation."
"Sanofi is not aware of any preliminary investigation on its 2017 accounts or other matter by the Parquet National Financier. We stand by the accuracy of our accounts," Sanofi said.
"Sanofi is not aware of any preliminary investigation on its 2017 accounts or other matter by the Parquet National Financier. We stand by the accuracy of our accounts," Sanofi said in an emailed statement.Sign up for NBC DFW newsletters"As a listed company, the financial information published by Sanofi is accurate, precise and sincere, and is duly audited by two auditing firms. Sanofi reserves the right to take legal action against any false or defamatory allegations.
The pharmaceutical giant late last month reduced its forecasts for 2024/5 and saw its share price fall sharply, now down 6.8% on the year.